Otsuka Dermatitis Candidate Looks Good At Phase III
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
You may also be interested in...
One analyst said efficacy data for roflumilast in INTEGUMENT-1 suggest limited competitiveness against Incyte’s topical JAK inhibitor, Opzelura, while others were more optimistic.
Denmark-based UNION therapeutics has bought LEO Pharma’s PDE4 inhibitor compound series for use in developing treatments for psoriasis and atopic dermatitis.
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.